> ## Content Index
> Fetch the complete content index at: https://med-techinsights.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Skin Analytics Secures £15M to Expand AI Skin Cancer Detection Globally
- URL: https://med-techinsights.com/skin-analytics-secures-15m-to-expand-ai-skin-cancer-detection-globally/
- Published: 2025-04-25T09:01:19.000Z
- Updated: 2026-10-23T06:31:16.000Z
- Description: Skin Analytics raises £15M to expand AI skin cancer detection globally following CE mark for autonomous diagnosis. Now entering new markets beyond the UK.
- Author: Med-Tech Insights Staff
- Tags: Digital Health & AI, News, Artificial Intelligence

[Skin Analytics](https://skin-analytics.com/?ref=med-techinsights.com), the UK-based healthtech company developing AI tools for [early skin cancer detection](https://med-techinsights.com/2025/02/06/worlds-first-ai-skin-cancer-detection-approved-in-europe/), has raised £15 million in Series B funding. The round was led by Intrepid Growth Partners, a specialist AI investment firm. This will support international expansion and further product development.

The investment follows a significant regulatory milestone for Skin Analytics. Its AI platform, DERM, has become the first autonomous skin cancer detection tool to receive a Class III CE mark under the EU Medical Device Regulation. This makes it the first legally approved AI device in the world. It is capable of making skin cancer diagnoses without human oversight.

### Addressing global pressures on dermatology services

Healthcare systems globally are under increasing strain, with a widespread shortage of dermatologists contributing to long wait times for cancer screening. In Europe, there are on average just 30 dermatologists per million people. Meanwhile, skin concerns remain one of the most common reasons for visiting a doctor.

Skin Analytics’ technology aims to ease this pressure by enabling faster, more accurate assessments. The company has already deployed its platform across 26 NHS sites. It has helped assess over 150,000 patients and detect more than 14,000 cases of skin cancer.

> “AI allows us to move from a world of specialist scarcity to one where everyone can access timely skin assessments,” said Neil Daly, CEO and founder of Skin Analytics. “This funding enables us to bring that vision to more people around the world.”

DERM has shown high levels of clinical accuracy, ruling out the most concerning forms of skin cancer with 99.8% accuracy. This figure exceeds the 98.9% benchmark set by human dermatologists. In UK trials, the system has reduced unnecessary face-to-face appointments by up to 95%. This has helped free up capacity for urgent cases.

### Plans for growth

Skin Analytics plans to use the funding to expand internationally, targeting key regions. These include Europe and Australia, where access to dermatologists is limited. The company will also accelerate its move into the United States. It aims to expand its technology to cover a broader range of dermatological conditions.

> “We’ve proven this model in the NHS,” said Daly. “Now it’s time to make it available more widely.”

The Series B round was led by Intrepid Growth Partners. Their founders include Mark Machin (former CEO of CPPIB), Mark Shulgan (former Head of Growth Equity at OMERS), and Professor Ajay Agrawal (University of Toronto), a noted expert on the economics of AI.

> “Skin Analytics is a strong example of machine intelligence being used to solve critical healthcare challenges,” said Machin. “We’re proud to support their expansion and help bring this technology to more patients around the world.”

The company is currently hiring. They are focusing on attracting AI engineers and clinical experts who want to play a role in reshaping the future of skin cancer care.